MSP008-22
/ Godavari Biorefineries
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
July 07, 2025
Godavari Biorefineries' patent for anticancer molecule validated in Spain, UK and EU
(CNBC-TV18)
- "Godavari Biorefineries on Monday (July 7) announced that its European patent for a novel anti-cancer molecule has been successfully validated in Spain, the United Kingdom, and as a unitary patent across multiple European Union member states....In a stock exchange filing, Godavari Biorefineries said that the patented molecule has demonstrated efficacy against both cancer cells and cancer stem cells and is being explored as a potential therapy for various cancers, including breast and prostate cancer."
Patent • Breast Cancer • Prostate Cancer
July 17, 2023
Sathgen Therapeutics announces completion of first cohort in phase 1 clinical trial with anti-cancer drug
(ExpressPharma)
- "Sathgen Therapeutics...announced the completion of the first cohort in a Phase 1 clinical trial with their first-in-class New Chemical Entity (NCE), MSP008-22....Sathgen aims to develop MSP008-22 for difficult-to-treat cancers, starting with triple negative breast cancer (TNBC) and prostate cancer as proof-of-principle. The lead molecule targets both the bulk cancer cells as well as the treatment-resistant population, making it an exciting prospect against various types of aggressive cancers. Moreover, this NCE did not present any adverse events in the first cohort."
Trial status • Breast Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer
September 08, 2022
Phase One Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of MSP008-22 in Healthy Adult Volunteers
(clinicaltrials.gov)
- P1 | N=72 | Not yet recruiting | Sponsor: Godavari Biorefineries Limited
New P1 trial • Infectious Disease • Novel Coronavirus Disease
July 28, 2022
Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours
(clinicaltrials.gov)
- P1 | N=27 | Not yet recruiting | Sponsor: Godavari Biorefineries Limited
New P1 trial • Breast Cancer • Head and Neck Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer
1 to 4
Of
4
Go to page
1